Gossamer Bio Announces Data Presentations at the Congress of the European Crohn’s and Colitis Organisation

SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present two posters with data on its GB004 program at the 15th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO) being held February 12- 15 in Vienna, Austria. Details for the ECCO presentations are a

Click to view original post